<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14686">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915705</url>
  </required_header>
  <id_info>
    <org_study_id>UX023-CL301</org_study_id>
    <nct_id>NCT02915705</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)</brief_title>
  <acronym>PIXLES</acronym>
  <official_title>A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      UX023-CL301 is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy
      and safety of KRN23 with active control (oral phosphate/active vitamin D therapy) in
      children with XLH (aged 1 to ≤12 years) who have radiographic evidence of rickets, open
      epiphyses, and have received oral phosphate/active vitamin D therapy for ≥ 6-12 consecutive
      months prior to screening. Approximately 60 subjects will be randomized 1:1 to receive
      open-label KRN23 administered by subcutaneous injection or oral phosphate and active vitamin
      D therapy for a total of 64 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in rickets in children with XLH</measure>
    <time_frame>40 weeks</time_frame>
    <description>Change in rickets at Week 40 as assessed by the RGI-C global score compared between the KRN23 and active control groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Phosphorous</measure>
    <time_frame>64 weeks</time_frame>
    <description>Effect of KRN23 as compared with active control by change from baseline in serum phosphorous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum 1,25(OH)D</measure>
    <time_frame>64 weeks</time_frame>
    <description>Effect of KRN23 as compared with active control by change from baseline in serum 1,25(OH)D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking ability using the Six Minute Walk Test (6MWT)</measure>
    <time_frame>24, 40 and 64 weeks</time_frame>
    <description>Change from baseline in total distance walked</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth</measure>
    <time_frame>24, 40 and 64 weeks</time_frame>
    <description>Change from baseline in standing height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient/Parent reported pain, fatigue and physical function/mobility</measure>
    <time_frame>24, 40 and 64 weeks</time_frame>
    <description>Change from baseline using the Patient Reported Outcomes Measurement Information System (PROMIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phamacokinetics throughout the dosing cycle</measure>
    <time_frame>64 weeks</time_frame>
    <description>Measure the concentration of KRN23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, frequency, and severity of AE's and SAE's</measure>
    <time_frame>64 weeks</time_frame>
    <description>Incidence compared against active control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>X-Linked Hypophosphatemia</condition>
  <arm_group>
    <arm_group_label>KRN23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized 1:1 to receive 0.8 mg/kg starting dose, administered every 2 weeks by subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized 1:1 to receive multiple daily doses of oral Phosphate and Active Vitamin D therapy, individualized for each subject at the Investigator's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KRN23</intervention_name>
    <description>KRN23 is a recombinant human immunoglobulin G isotype 1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).</description>
    <arm_group_label>KRN23</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Phosphate</intervention_name>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Vitamin D</intervention_name>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, aged 1 to ≤12 years with radiographic evidence of rickets as
             determined by central read

          2. PHEX mutation or variant of uncertain significance in either the patient or in a
             directly related family member with appropriate X-linked inheritance

          3. Biochemical findings associated with XLH: Serum phosphorus &lt;3.0 mg/dL (0.97 mmol/L)

          4. Serum creatinine within age-adjusted normal range

          5. Serum 25(OH)D above the lower limit of normal (≥16 ng/mL) at the Screening Visit

          6. Have received both oral phosphate and active vitamin D therapy for ≥ 12 consecutive
             months (for children ≥3 years of age) or ≥ 6 consecutive months (for children &lt;3
             years of age) prior to the Screening Visit

          7. Willing to provide access to prior medical records for the collection of historical
             growth and radiographic data and disease history.

          8. Provide written or verbal assent (as appropriate for the subject and region) and
             written informed consent by a legally authorized representative after the nature of
             the study has been explained, and prior to any research-related procedures.

          9. Must, in the opinion of the investigator, be willing and able to complete all aspects
             of the study, adhere to the study visit schedule and comply with the assessments.

         10. Females who have reached menarche must have a negative pregnancy test at Screening
             and undergo additional pregnancy testing during the study. If sexually active, male
             and female subjects must be willing to use highly effective method(s) of
             contraception for the duration of the study.

        Exclusion Criteria:

          1. Tanner stage 4 or higher through physical examination

          2. Height percentile &gt;50% based on country-specific norms

          3. Use of aluminum hydroxide antacids (e.g. Maalox® and Mylanta®), systemic
             corticosteroids, acetazolamide, and thiazides within 7 days prior to the Screening
             Visit

          4. Current or prior use of leuprorelin (e.g., Lupron®, Viadur®, Eligard®), triptorelin
             (TRELSTAR®), goserelin (Zoladex®), or other drugs known to delay puberty

          5. Use of growth hormone therapy within 12 months before the Screening Visit

          6. Presence of nephrocalcinosis on renal ultrasound grade 4

          7. Planned or recommended orthopedic surgery, including staples, 8-plates or osteotomy,
             within the clinical trial period

          8. Hypocalcemia or hypercalcemia, defined as serum calcium levels outside the
             age-adjusted normal limits

          9. Evidence of hyperparathyroidism (PTH levels 2.5X upper limit of normal [ULN])

         10. Use of medication to suppress PTH (e.g., cinacalcet, calcimimetics) within 2 months
             prior to the Screening Visit

         11. Presence or history of any condition that, in the view of the investigator, places
             the subject at high risk of poor treatment compliance or of not completing the study.

         12. Presence of a concurrent disease or condition that would interfere with study
             participation or affect safety

         13. History of recurrent infection or predisposition to infection, or of known
             immunodeficiency

         14. Use of a therapeutic monoclonal antibody within 90 days prior to the Screening Visit
             or history of allergic or anaphylactic reactions to any monoclonal antibody

         15. Presence or history of any hypersensitivity to KRN23 excipients that, in the judgment
             of the investigator, places the subject at increased risk for adverse effects.

         16. Use of any investigational product or investigational medical device within 30 days
             prior to screening, or requirement for any investigational agent prior to completion
             of all scheduled study assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kimberly Trant</last_name>
    <phone>415-483-8125</phone>
    <email>KTrant@ultragenyx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Guzman</last_name>
      <phone>323-361-8633</phone>
      <email>vguzman@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Pisit Pitkcheewanont</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Fang</last_name>
      <phone>415-476-3557</phone>
      <email>melissa.fang@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Portale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Hart</last_name>
      <phone>317-948-8346</phone>
      <email>marihart@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Erik Imel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital For Children</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Cox</last_name>
      <phone>314-432-3600</phone>
      <phone_ext>1110</phone_ext>
      <email>ecox@shrinenet.org</email>
    </contact>
    <investigator>
      <last_name>Michael Whyte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-9170</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margo Black</last_name>
      <phone>615-343-5846</phone>
      <email>margo.black@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Jill Simmons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital Network</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Foxall</last_name>
      <phone>61 2 984 53147</phone>
      <email>LynneF@chw.edu.au</email>
    </contact>
    <investigator>
      <last_name>Craig Munns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario (CHEO) Research Institute</name>
      <address>
        <city>Ottowa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danielle Cram</last_name>
      <phone>613-737-7600</phone>
      <phone_ext>4124</phone_ext>
      <email>dcram@cheo.on.ca</email>
    </contact>
    <investigator>
      <last_name>Leanne Ward, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SickKids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Tschrihart</last_name>
      <phone>416-813-8407</phone>
      <email>holly.tschirhart@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Etienne Sochett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children - Canada</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michaela Durigova</last_name>
      <phone>514-282-7158</phone>
      <email>mdurigova@shriners.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Francis Glorieux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ODense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Ronning</last_name>
      <phone>+45 30493237</phone>
      <email>Louise.Ronning-Baek@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Henrik Christesen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital University Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monika Kron</last_name>
      <phone>+49 221 478 84747</phone>
      <email>monika.kron@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Jorg Semler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Magdeburg A. oe. R.-Otto-von-Guericke Universty</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Empting</last_name>
      <phone>+49 221 478 84747</phone>
      <email>susann.empting@med.ovgu.de</email>
    </contact>
    <investigator>
      <last_name>Klaus Mohnike</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>1</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aoife Carey</last_name>
      <phone>+353 1 892 1846</phone>
      <email>aoife.mcarey@cuh.ie</email>
    </contact>
    <investigator>
      <last_name>Ciara McDonnell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florence</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Fossi</last_name>
      <phone>+39 055 7946303</phone>
      <email>caterina.fossi@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Maria Luisa Brandi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele)</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesús Argente</last_name>
      <phone>+34 915035915</phone>
      <email>jesus.argente@fundacionendo.org</email>
    </contact>
    <investigator>
      <last_name>Stefano Mora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Auxologico Italiano</name>
      <address>
        <city>Milan</city>
        <zip>20145</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Vai</last_name>
      <phone>+39 02 619112438</phone>
      <email>s.vai@auxologico.it</email>
    </contact>
    <investigator>
      <last_name>Maria Luisa Bianchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Pediatria 1, AOUP</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giampiero Baroncelli</last_name>
      <phone>+39 050 993 168</phone>
      <email>g.baroncelli@med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Giampiero Baroncelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Chidren's Medical Center</name>
      <address>
        <city>Obu</city>
        <state>Aichi</state>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ichi Tobo</last_name>
      <phone>81-562-43-0500</phone>
      <email>shoni-tiken@sk00106.achmc.pref.aichi.jp</email>
    </contact>
    <investigator>
      <last_name>Takashi Hamajima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hyogo Prefectural Kobe Children's Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>654-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoshi Kishimoto</last_name>
      <phone>81-78-360-1655</phone>
      <email>kishimoto.satoshi@e-smo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Katsumi Goji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Koji Muroya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Takuo Kubota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai General Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hiroyuki Tanaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Japan Community Healthcare Organization Osaka Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunihiko Tanaka</last_name>
      <phone>81-6-6441-5451</phone>
      <email>chiken_soudan@okn.gr.jp</email>
    </contact>
    <investigator>
      <last_name>Noriyuki Namba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center for Child Health and Development</name>
      <address>
        <city>Tokyo</city>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reiko Horikawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>YuKyoung Yun</last_name>
      <phone>82-10-9168-0875</phone>
      <email>miso6060@naver.com</email>
    </contact>
    <investigator>
      <last_name>Hae II Cheong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Martin</last_name>
      <phone>+34 606 968 517</phone>
      <email>smartinp@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Gabriel Martos-Moreno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet and University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ola Nilsson</last_name>
      <phone>+46 8 5177 9710</phone>
      <email>ola.nilsson@ki.se</email>
    </contact>
    <investigator>
      <last_name>Ola Nilsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire Smith</last_name>
      <phone>+44 121 333 9156</phone>
      <email>Claire.Harris@bch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Hogler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital - University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Cox</last_name>
    </contact>
    <contact_backup>
      <phone>+44 0161 701 1720</phone>
      <email>Rachel.Cox@cmft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Raja Padidela</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 13, 2017</lastchanged_date>
  <firstreceived_date>May 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
